GlassScriptPhysician profile
Erick W Hjortsvang
NPI 1275611857
$4,425.04
in general payments reported to CMS, 2019-2025
32 companies · $692 in 2025
The $692 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $418 · 2021: $1,183 · 2022: $517 · 2023: $462 · 2024: $517 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289 · Long Term Medical Supply Or Device Loan: $366 · Education: $16.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,288.59 |
| Long Term Medical Supply Or Device Loan | $366.06 |
| Education | $16.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,468.16 | 2019-2025 | |
| Seagen INC. | $271.62 | 2019-2023 | Adcetris |
| Astrazeneca Pharmaceuticals LP | $185.17 | 2023-2025 | Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $179.15 | 2023-2025 | Keytruda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.02 | 2019-2022 | |
| Eisai INC. | $176.20 | 2023-2025 | |
| Abbvie INC. | $110.30 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $97.24 | 2022-2024 | Libtayo |
| Janssen Biotech, INC. | $77.35 | 2024-2025 | Talvey, Darzalex, Tecvayli |
| Agios Pharmaceuticals, INC. | $71.26 | 2024-2025 | Pyrukynd |
| Pharmacyclics LLC, An Abbvie Company | $65.77 | 2019-2020 | |
| Secura Bio, INC. | $49.14 | 2022-2023 | Copiktra |
| Exelixis INC. | $42.15 | 2024-2025 | Cabometyx |
| Astellas Pharma US INC | $40.28 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.78 | 2022-2023 | Ninlaro |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $38.85 | 2024-2025 | |
| Genentech USA, INC. | $35.91 | 2025 | Polivy |
| Mirati Therapeutics, INC. | $31.34 | 2024 | Krazati |
| Caris Mpi, INC. | $28.59 | 2025 | Mi Cancer Seek |
| Daiichi Sankyo INC. | $27.27 | 2024 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $26.53 | 2025 | |
| Emd Serono, INC. | $23.19 | 2024 | |
| Foundation Medicine, INC. | $21.80 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $21.63 | 2021 | |
| Alexion Pharmaceuticals, INC. | $21.13 | 2021 | |
| Sobi, INC | $18.02 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $16.23 | 2023 | Onivyde |
| Celgene Corporation | $13.88 | 2023 | Reblozyl |
| Glaxosmithkline, LLC. | $13.76 | 2021 | |
| Puma Biotechnology, INC. | $13.56 | 2024 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Heron Therapeutics, INC. | $8.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erick Hjortsvang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.